. Author manuscript; available in PMC: 2018 Jun 28.

Published in final edited form as: J Hepatol. 2010 Jun 20;53(4):671–676. doi: 10.1016/j.jhep.2010.04.032

Table 3.

HBV BCP mutations in HCC cases and controls.

BCP Mutations		Controls (%)	Cases (%)	OR (95% CI)^*	Adjusted OR (95%CI)
1762^T/1764^A mutations	No (1762^A/1764^G)	31(25.8)	5 (8.3)	1.00	1.00
1762^T/1764^A mutations	Yes (1762^T/1764^G or 1762^T/1764^A)^**	89(74.1)	55(91.7)^***	3.83(1.41–10.41)	3.89(1.40–10.77)^#
1753^V mutations	No (1753^T)	89 (74.2)	30 (50.0)	1.00	1.00
1753^V mutations	Yes (1753^CAG)	31(25.8)	30(50.0)^***	2.87 (1.50–5.50)	2.78(1.43–5.40)^##
1752^V mutations	No (1752^A)	116 (96.7)	50(83.3)	1.00	1.00
1752^V mutations	Yes (1752^TCG)	4 (3.3)	10(16.7)^***	5.80(1.74–19.37)	5.96(1.75–20.25)^#

OR, odds ratio; CI, confidence interval

^**

1 single mutation (1762^T/1764^G) was found in control group, all others were 1762^T/1764^A double mutations.

^***

p <0.05 from unconditional logistic regression in comparing the distribution of mutations in cases and controls

adjusted for age, gender, first-degree family history of cancer;

^##

adjusted for age, gender, alcohol drinking status, first-degree family history of cancer.